Yungjin files 'KT&G101’ application for marketing approval with KFDA

Biopid Co., a local biopharmaceutical company, said yesterday that its partner, Yungjin Pharma, has filed a marketing application for a new drug 'KT&G101’ for treatment of atopic dermatitis with the Korea Food and Drug Administration.

“KT&G101 possesses anti-inflammatory and related antinociceptive and anti-angiogenic activities, which indirectly supports its use as an anti-atopic therapy,” ...